MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3324/haematol.2025.288549

Медицинская библиотека · Haematologica · 2026

Autoimmune cytopenias following alemtuzumab-induced renal transplant: clinical features and treatment outcomes.

Lucchini Elisa, Kamuriwo Lucy, Gleeson Sarah, Ademokun Christine, Atta Maria, Luqmani Asad, Deplano Simona, Layton Mark, Hart Alice, Sohal Mamta, Okoli Steven, Vladescu Camelia, Paul Deena, Saputil Rocel, Szydlo Richard, Kousios Andreas, Charif Rawya, Cooper Nichola

СтатьяПеревод в очереди

Аннотация

The anti-CD52 monoclonal antibody, alemtuzumab, is used as induction therapy for renal transplantation. Its use has been associated with autoimmune manifestations, particularly autoimmune cytopenias (AICs). Here, we report a single-center, retrospective analysis of patients who developed AICs after an alemtuzumab-induced renal transplant. Over a period of 8 years, 40 renal transplant patients developed immune thrombocytopenia (ITP) (n=28), autoimmune hemolytic anemia (AIHA) (n=7) or Evans syndrome (ES) (n=5), with two peaks of incidence, at 18 and 36 months after alemtuzumab. Response and relapse rates to standard first-line ITP and AIHA therapy were comparable to primary forms, with two thirds requiring second-line agents. Most patients with ITP who failed to go into remission after steroids or IVIG received either rituximab or a thrombopoietin receptor agonist (TPO-RA). Compared to primary ITP, a higher response rate (91.6%) and median duration of response (56 months) were achieved with rituximab; and a higher proportion of patients were able to discontinue TPO-RAs and maintain remission (50%). Most patients experienced one or more adverse events, most commonly, infections (62.5%), cardiovascular diseases (27.5%) and deep vein thrombosis (25%). In conclusion, AICs are a significant complication following alemtuzumab-induced renal transplantation, typically occurring within the 5-year period of immune reconstitution. Both rituximab and TPO-RAs show good efficacy, a few patients develop multi refractory disease, and the majority go into sustained remission off-treatment. Given that treatment is complicated by high rates of infections and thrombosis, supportive measures using antimicrobials as well as quick re-introduction of antiplatelet or anticoagulants in ITP and addition of anticoagulation in AIHA is recommended.

Для цитирования: Lucchini Elisa, Kamuriwo Lucy, Gleeson Sarah, Ademokun Christine, Atta Maria, Luqmani Asad, Deplano Simona, Layton Mark, Hart Alice, Sohal Mamta, Okoli Steven, Vladescu Camelia, Paul Deena, Saputil Rocel, Szydlo Richard, Kousios Andreas, Charif Rawya, Cooper Nichola. Autoimmune cytopenias following alemtuzumab-induced renal transplant: clinical features and treatment outcomes.. Haematologica. 2026. DOI: 10.3324/haematol.2025.288549.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.